AIxCrypto Holdings Stock (NASDAQ:AIXC)

Financials Chart

Previous Close

$2.69

52W Range

$1.61 - $8.81

50D Avg

$2.63

200D Avg

$3.12

Market Cap

$13.21M

Avg Vol (3M)

$1.23M

Beta

0.30

Div Yield

AIXC Company Profile

AIxCrypto Holdings, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was formerly known as Qualigen Therapeutics, Inc. and changed its name to AIxCrypto Holdings, Inc. in November 2025. The company was founded in 1996 and is based in Carlsbad, California.

Industry

Medical - Pharmaceuticals

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Jun 23, 2015

Website

AIXC Performance

AIXC Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-5.76M	$-11.30M	$-14.76M
Net Income	$-6.26M	$-13.42M	$-18.64M
EBITDA	$-5.24M	$-10.95M	$-13.84M
Basic EPS	$-17.55	$-132.25	$-243.00
Diluted EPS	$-17.55	$-132.25	$-243.00

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
JG	Aurora Mobile Limited
OLB	The OLB Group, Inc.
AUID	authID Inc.
CTOR	Citius Oncology, Inc.
ATGL	Alpha Technology Group Limited
IMXI	International Money Express, Inc.
CWD	CaliberCos Inc.